Literature DB >> 3171625

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation.

P Mauch1, N Tarbell, H Weinstein, B Silver, T Goffman, R Osteen, A Zajac, C N Coleman, G Canellos, D Rosenthal.   

Abstract

A total of 315 pathologically staged (PS) patients with IA and IIA Hodgkin's disease (HD) were treated with mantle and paraaortic irradiation, and evaluated for freedom-from-first relapse (FFR), survival, prognostic factors, and long-term complications. The 14-year actuarial FFR and survival were 82% and 93%, respectively, with a median follow-up time of 9 years. Mediastinal size was the only factor that predicted for a lower FFR, P less than .001. Forty-nine patients have developed recurrent HD. Thirty-six patients are disease-free following retreatment and only 13 patients have died of HD. Patients with mixed cellularity (MC) histology were more likely to relapse below the diaphragm (11%) as compared with patients with nodular sclerosis (NS) (5.1%) or lymphocyte predominant (LP) (3.6%) histology. These relapses were often associated with bulky pelvic nodal adenopathy and salvage treatment with chemotherapy alone often failed to control recurrent disease. Alternative diagnostic and therapeutic recommendations are presented for these patients. Thyroid abnormalities represented the most common long-term complication with an actuarial risk at 16 years of 37%. Major complications were rare. Mantle and paraaortic irradiation is associated with a high FFR and a low risk of complications and should remain standard treatment for early-stage HD.

Entities:  

Mesh:

Year:  1988        PMID: 3171625     DOI: 10.1200/JCO.1988.6.10.1576

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

Review 1.  Prognostic factors in pediatric Hodgkin disease.

Authors:  Cindy L Schwartz
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

Review 2.  Hodgkin's lymphoma. II: Treatment and delayed morbidity.

Authors:  P Carde
Journal:  BMJ       Date:  1992-07-18

Review 3.  Hodgkin's disease--I: Identification and classification.

Authors:  P Carde
Journal:  BMJ       Date:  1992-07-11

Review 4.  Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy?

Authors:  Gregory M Cote; George P Canellos
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

Review 5.  Early stage Hodgkin's disease in adults: which is the correct treatment?

Authors:  M Brada
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

Review 6.  ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

Authors:  Sughosh Dhakal; Ranjana Advani; Leslie K Ballas; Bouthaina S Dabaja; Christopher R Flowers; Chul S Ha; Bradford S Hoppe; Nancy P Mendenhall; Monika L Metzger; John P Plastaras; Kenneth B Roberts; Ronald Shapiro; Sonali M Smith; Stephanie A Terezakis; Karen M Winkfield; Anas Younes; Louis S Constine
Journal:  Am J Clin Oncol       Date:  2016-12       Impact factor: 2.339

7.  A 37-year-old man with cholestatic jaundice and a prior history of Hodgkin's disease.

Authors:  M Hoogendoorn; J H van Krieken; R Bieger
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

Review 8.  Long-term complications of laparotomy in Hodgkin's disease.

Authors:  M Jockovich; N P Mendenhall; M D Sombeck; J L Talbert; E M Copeland; K I Bland
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

9.  Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma.

Authors:  Kheng-Wei Yeoh; N George Mikhaeel
Journal:  Adv Hematol       Date:  2010-10-24

10.  Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital.

Authors:  T S Ganesan; P F Wrigley; P A Murray; A G Stansfeld; A J d'Ardenne; S Arnott; A Jones; W S Shand; J S Malpas; T A Lister
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.